Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Peritoneal Neoplasms 1Ovarian Neoplasms 1Colorectal Neoplasms 1

Interventions

Fluorouracil 131Leucovorin 127Oxaliplatin 93Bevacizumab 86Irinotecan 74Capecitabine 63Cetuximab 47Folfox protocol 32Panitumumab 18regorafenib 16trifluridine tipiracil drug combination 15Drug Therapy 14Chemotherapy, Adjuvant 13IFL protocol 10Floxuridine 10Radiotherapy 9Tegafur 7Neoadjuvant Therapy 7Levoleucovorin 7Laparoscopy 7Aspirin 7pembrolizumab 6atezolizumab 6Trifluridine 6Celecoxib 6XELOX 5Mitomycin 5Colonoscopy 5tipiracil 4sintilimab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Colorectal Neoplasms × nintedanib × Clear all
NCT02149108 2017-07-21

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

Boehringer Ingelheim

Phase 3 Completed
768 enrolled 10 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡